152 related articles for article (PubMed ID: 6401216)
1. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.
Hilgartner MW; Knatterud GL
Blood; 1983 Jan; 61(1):36-40. PubMed ID: 6401216
[TBL] [Abstract][Full Text] [Related]
2. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
[TBL] [Abstract][Full Text] [Related]
3. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
Zwahlen H; Beck EA
Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
[TBL] [Abstract][Full Text] [Related]
4. Hemophiliacs with inhibitors: therapeutic options.
Roberts HR
N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992
[No Abstract] [Full Text] [Related]
5. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
Iizuka A; Kuwashima M; Nagao T
Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
[No Abstract] [Full Text] [Related]
8. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
[TBL] [Abstract][Full Text] [Related]
9. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
10. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
[No Abstract] [Full Text] [Related]
11. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
Parry DH; Bloom AL
J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular hemorrhage in hemophiliacs with inhibitors. A medical emergency.
Scranton PE; Hasiba U; Gorenc TJ
JAMA; 1979 May; 241(19):2028-30. PubMed ID: 430796
[TBL] [Abstract][Full Text] [Related]
13. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.
Tjønnfjord GE; Brinch L; Gedde-Dahl T; Brosstad FR
Haemophilia; 2004 Mar; 10(2):174-8. PubMed ID: 14962207
[TBL] [Abstract][Full Text] [Related]
14. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
15. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
Verroust F; Moussard C; Allain JP
Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
[TBL] [Abstract][Full Text] [Related]
16. Use of FEIBA and Amicar in the operating room--dental treatment of a patient with hemophilia and high titer factor VIII inhibitors.
Sharp HK; McIlveen LP; Schuman NJ
Spec Care Dentist; 1986; 6(5):210-2. PubMed ID: 2945270
[No Abstract] [Full Text] [Related]
17. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
18. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
István L; Bariska I; Marton E
Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
[No Abstract] [Full Text] [Related]
20. Resistance to activated F IX concentrate (FEIBA).
Stenbjerg S; Jorgensen J
Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
